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Background: X-chromosome-linked IAP (XIAP) and nuclear factor-κB (NF-κB) are frequently overexpressed and correlate
closely with chemoradiotherapy resistance and poor prognosis in many cancers. However, the significance of XIAP and
NF-κB expression in radiotherapy sensitivity and its effect on the prognosis of esophageal squamous cell carcinoma
(ESCC) are still unknown. The aim of this study was to examine XIAP and NF-κB status in ESCC patients undergoing
postoperative radiotherapy after radical surgery, and to evaluate their clinical significance.
Methods: A total of 78 ESCC patients treated with postoperative radiotherapy after radical surgery were
enrolled in this study. We immunohistochemically investigated the expression of XIAP and NF-κB in tissues from
enrolled patients with specific antibodies. Then, the correlations among XIAP, NF-κB expression, clinicopathological
features and its prognostic relevance in ESCC were analyzed.
Results: The increased expression of XIAP and NF-κB in ESCC tissues were clearly correlated with the tumor
differentiation and p-TNM stage. Significant positive correlations were found between the expression status of
XIAP and NF-κB (r = 0.779, P = 0.000). Overexpression of XIAP and NF-κB and metastasis were significantly associated
with shorter overall survival times in univariate analysis (P < 0.05). Multivariate analysis also confirmed that XIAP
expression was an independent prognostic factor (P = 0.005).
Conclusions: XIAP and NF-κB are intensively expressed in ESCC. The level of XIAP is positively correlated to progression
and prognosis of ESCC.
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Esophageal cancer is one of the most aggressive and le-
thal malignancies, and esophageal squamous cell carcin-
oma (ESCC) is the major histologic form of esophageal
cancer [1]. Surgery is still the mainstay treatment for pa-
tients with esophageal cancer, however, the five-year risk
of the operable recurrence is 70% to 80% [2,3]. Postoper-
ative radiotherapy as an adjuvant therapy is being used
more often to improve the outcome of ESCC patients
after surgery [2]. However, not all patients with ESCC
benefit from radiotherapy, and there are individual dif-
ferences in response to postoperative radiotherapy. The* Correspondence: zmx3115@163.com; Liangjtangdu@163.com
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reproduction in any medium, provided the oroutcomes vary greatly and unpredictably, and the sur-
vival of responders has been reported to be better than
that of non-responders [4,5]. It is important to recognize
the probable treatment response in these tumors. The
main obstacle to this approach is the lack of availability
of prognostic biomarkers. Pretreatment clinical parame-
ters such as gender, age, TNM classification, and tumor
differentiation are not effective in predicting the biologic
behavior of ESCC patients who receive postoperative
radiotherapy. Thus, it is necessary to identify available
biomarkers for predicting response and treatment out-
comes of postoperative radiotherapy in ESCC patients.
Among the molecular pathways potentially involved in
generating the differential response to radiotherapy, an
association has consistently been observed between the
apoptotic pathway and the tumor radiosensitivity [4,5].td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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dogenous antiapoptotic proteins [6]. Among the eight
human IAP proteins, X-chromosome-linked IAP (XIAP)
has been reported to exert the most pronounced antia-
poptotic function, which has been linked to its ability to
bind to caspase-3, -7 and -9 [7]. Firstly, a number of
studies have demonstrated that elevated expression
levels of XIAP in many types of tumors correlates
with a poor prognosis [8]. Secondly, both in vitro and
in vivo studies have further demonstrated that down-
regulation of XIAP expression, either by RNA inter-
ference (RNAi) or antisense oligonucleotides, results
in stimulation of sensitization to gamma-irradiation
and chemotherapeutic-induced apoptosis in tumor
cells [9-12]. Likewise, XIAP has been found to be
highly expressed in ESCC, and its downregulation by
RNAi sensitizes ESCC cell lines to chemotherapeutics
[13]. Additionally, more and more research has shown
that XIAP acts as a radioresistance factor for radiotherapy
in human cancers [14-19]. However, whether XIAP can
play a role as a prognostic marker for radiotherapy in ESCC
patients has not been extensively investigated to date.
Moreover, aberrant nuclear factor-κB (NF-κB) expres-
sion has been detected in many human malignancies.
NF-κB is a transcription factor that regulates the expres-
sion of genes linked to inflammation, apoptosis, survival,
proliferation, invasion, angiogenesis, metastasis, chemore-
sistance, tumor cell transformation, and radioresistance
[20]. NF-κB may activate the expression of several genes
or proteins that are involved in the apoptotic regulation,
such as IAPs [21]. Furthermore, XIAP has also been impli-
cated in the regulation of NF-κB activation [22]. On the
other hand, NF-κB may be responsible for blocking the ef-
ficacy of chemotherapy and radiation in some types of
tumor cells. The positive correlation between NF-κB
expression in ESCC and their resistance to chemoradi-
ation therapy has been previously reported [23], but
more specific studies are required to confirm the sig-
nificance of NF-κB in predicting disease progression in
postoperative radiotherapy of ESCC.
The aim of this study was to determine the prognostic
significance of XIAP and NF-κB in terms of overall sur-
vival in ESCC treated with surgery followed by radio-
therapy. This was done by using immunohistochemical
staining to explore the potential markers in 78 ESCC pa-
tients who underwent a surgical resection and postoper-
ative radiotherapy. We also investigated whether the
expression levels of XIAP correlate with that of NF-κB
in this patient population.
Methods
Patients and specimens
A total of 88 patients with ESCC were selected for this
study between January 2000 and December 2007 in theTangdu Hospital of Fourth Military Medical University
and First Affiliated Hospital of Medical School of Xi’an
Jiaotong University. Of these, the tumor staging, clinico-
pathological information, or follow-up was incomplete
for ten patients. As a result, 78 patients were retrospect-
ively reviewed. In addition, patients were required to
meet the following criteria: (1) all ESCC cases were
pathology confirmed; (2) no distant metastasis (except to
the supraclavicular and celiac lymph nodes); (3) the pa-
tients completed the whole course of radiotherapy; (4)
the patients received preoperative radiotherapy or
chemotherapy were excluded; (5) the patients received
postoperative chemotherapy or postoperative concurrent
chemoradiation were excluded. Tissue samples collected
during biopsy and surgery were formalin fixed and paraf-
fin embedded. The Institutional Ethics Committee ap-
proval for this study had been obtained from the Tangdu
hospital Institutional Review Board.
Surgery
All patients underwent radical surgery. The surgical ap-
proach consisted of a limited thoracotomy on the right
side and intrathoracic gastric tube reconstruction (Ivor-
Lewis procedure) for lesions in the middle/lower-third
of the esophagus. Upper-third lesions were treated by
neck anastomosis (Mckeown procedure). Patients under-
went two-field or three-field lymph node dissection (the
neck, mediastinum and abdomen) depending on the sur-
gical approach used.
Postoperative radiotherapy
The selection of postoperative adjuvant therapy was
made according to the individual physicians’ prefer-
ence and the general physical conditions of the patient.
Postoperative radiation was begun three to four weeks
after the surgery. All patients were treated using three-
dimensional conformal radiation therapy (3D-CRT) after
esophagectomy. The initial treatment volume included the
primary tumor and enlarged lymph nodes. The median ra-
diation dose of 48 Gy (40 to 50 Gy, 2 Gy per fraction, five
days per week) was delivered with a three- or four-field
technique in 20 to 25 fractions. The extent of the irradi-
ation field was determined based on the primary site in the
esophagus. For the lesions of the upper/middle-third of the
esophagus, the irradiation area included the tumor bed, bi-
lateral supraclavicular fossae, mediastinum, and subcarinal
area; for the lower-third lesions of the esophagus, the
tumor bed, bilateral supraclavicular fossae, mediastinum,
subcarinal area, and lower thoracic paraesophageal lymph
nodes area were irradiated.
Follow-up
Follow-up evaluations were performed every three to
four months after radiotherapy until the study was
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follow-up was 23.63 months (±13.14 months).
Immunohistochemical staining
Tissue specimens were fixed in neutral buffered formalin
(10% v/v formalin in water; pH 7.4) and embedded in
paraffin wax. Serial sections of 4 μm thickness were cut
and mounted on charged glass slides. The monoclonal
antibody against XIAP (1:100; Cell Signaling Technol-
ogy, Beverly, MA, USA) and NF-κB (1:200; Santa Cruz
Biotechnology, Santa Cruz, CA, USA) were used respect-
ively. The streptavidin-peroxidase technique (Golden Bridge
International: SP-9000, Mukilteo, Washington, USA) was
used according the manufacturer's instruction. An irrelevant
rabbit antiserum served as a negative control. Sections were
counterstained with Mayer’s hematoxylin.
Immunohistochemical analysis
Two observers who were blinded to clinical and follow-
up data evaluated staining results independently and co-
observed for a consensus when they were divergent.
Both the percentage of positive cells and the strength of
the staining were considered in the following method.
Five degree magnification visions were chosen randomly
under the optical microscope, the calculation of results
being as followed: the percentage of positive cells in 0%
to 5% was counted 0; the percentage of positive cells in
5% to 25% was counted 1; 26% to 50% was counted 2;
51% to 75% was counted 3; ≥ 76% was counted 4. InFigure 1 Immunohistochemical expression of X-linked-chromosome i
in esophageal squamous cell carcinoma (ESCC). (A) typical immunohist
staining shown cytoplasmic localization; (B) typical immunohistological fea
immunohistological features with high levels of NF-κB in ESCC. The NF-κ
(D) negative staining in ESCC. Magnifications × 200.respect of staining strength, the score for tumor cells
without stain is 0; straw yellow for 1; brown for 2; tan
for 3. The staining index score was the sum of the items
above. For the purpose of statistical analysis, 3 was used
as a cutoff value to distinguish tumors with a low (< 3)
or high (≥ 3) level of expression.
Statistical analysis
Data were analyzed using SPSS version 13.0 (SPSS Insti-
tute, Chicago, IL, USA). Fisher’s exact test was used to
analyze the correlation between staining index and other
categorical factors potentially predictive of prognosis.
The Spearman's rank correlation coefficient was used for
analyzing the association of NF-κB expression levels
with XIAP expression status. Overall survival was deter-
mined as the time (in months) from the date of surgery
to last follow-up or to 1 January 2013, for living patients
or to the date of death. Survival curve and median sur-
vival were estimated by the Kaplan-Meier method, and
the statistical differences between survival curves were
examined by the log-rank test. A Cox proportional haz-
ard regression model was used to perform multivariate
analyses. P < 0.05 was regarded as statistically significant.
Results
Expression of XIAP and NF-κB in ESCC and their
relationships to clinicopathological variables
Levels of XIAP and NF-κB were evaluated by immuno-
histochemical analysis. XIAP immunoreactivity showednhibitor of apoptosis (XIAP) protein and nuclear factor-κB (NF-κB)
ological features with high levels of XIAP expression in ESCC. The XIAP
tures with lower levels of XIAP expression in ESCC; (C) typical
B staining was present in the nucleus and cytoplasm of tumor cells;
Table 2 Association of nuclear factor-κB (NF-κB) expression
levels with X-linked-chromosome inhibitor of apoptosis
(XIAP) protein expression status
Variables Total XIAP P r
Low High
NF-κB 0.000 0.779
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cated in the nucleus and cytoplasm. Figure 1 shows rep-
resentative expression patterns of XIAP and NF-κB in
ESCC. The increased expression of XIAP and NF-κB in
ESCC tissues showed obvious correlation with the tumor
differentiation and p-TNM stage (Table 1).Low 20 18 2
High 58 5 53Association of XIAP expression levels with NF-κB
expression status
Since XIAP can activate the transcription factor NF-
κB, a known survival factor for cancer cells, we next
investigated the association of XIAP expression levels
with NF-κB expression status (Table 2). Of the 54 tu-
mors containing a high level of cytoplasmic XIAP im-
munoreactivity, a total of 51 cases displayed a highTable 1 Correlation of X-linked-chromosome inhibitor of
apoptosis (XIAP) protein and nuclear factor-κB (NF-κB)
expression to clinicopathologic characteristics of 78





Low High P-value Low High P-value
Gender
Male 15 33 0.800 12 36 1.000
Female 8 22 8 22
Age
< 60 13 35 0.615 13 35 0.794
≥ 60 10 20 7 23
Tumor location
Lower thoracic 14 30 0.628 10 34 0.603
Middle and Upper
thoracic
9 25 10 24
Length of tumor
< 5 cm 14 30 0.628 10 34 0.603
≥ 5 cm 9 25 10 24
T-stage
T3 12 41 0.066 14 39 1.000
T1-2 11 14 6 19
N-stage
N0 11 22 0.618 11 22 0.201
N1 12 33 9 36
p-TNM stage
I-II 13 15 0.020 12 16 0.014
III 10 40 8 42
Differentiation
Well and Medium 23 28 0.000 20 31 0.000
Poor 0 27 0 27expression of NF-κB. We calculated the Spearman's
rank correlation coefficient to evaluate the linear rela-
tionship. There was statistically significant association
of XIAP expression status with NF-κB expression
levels (r = 0.779, P = 0.000).Table 3 Univariate analysis for overall survival
Variables Total Overall survival P
Median ± SE 95% CI
XIAP 0.000
Low 23 44.00 ± 0.99 42.05 to 45.95
High 55 20.00 ± 1.30 17.45 to 22.55
NF-κB 0.000
Low 20 44.00 ± 1.20 41.66 to 46.34
High 58 20.00 ± 1.37 17.32 to 22.68
Gender 0.624
Male 48 22.00 ± 1.79 18.48 to 25.52
Female 30 30.00 ± 4.71 20.77 to 39.23
Age 0.956
< 60 48 22.00 ± 3.10 15.92 to 28.08
≥ 60 30 26.00 ± 5.11 15.98 to 36.02
Tumor location 0.421
Lower thoracic 44 22.00 ± 7.37 7.56 to 36.44
Middle and Upper thoracic 34 40.13 ± 5.68 19.58 to 28.42
Length of tumor 0.421
< 5 cm 44 24.00 ± 2.25 19.58 to 28.42
≥ 5 cm 34 22.00 ± 7.37 7.56 to 36.44
T-stage 0.202
T3 53 24.00 ± 2.59 18.93 to 29.07
T1-2 25 29.00 ± 5.34 18.53 to 39.47
N-stage 0.238
N0 33 24.00 ± 7.65 9.01 to 38.99
N1 45 24.00 ± 2.93 18.25 to 29.75
p-TNM stage 0.076
I-II 28 32.00 ± 2.82 26.48 to 37.52
III 50 20.00 ± 2.18 15.74 to 24.26
Differentiation 0.000
Well and Medium 51 34.00 ± 3.40 27.35 to 40.66
Poor 27 16.00 ± 2.43 11.24 to 20.76
Figure 2 Kaplan-Meier survival analysis. Progression free survival differences between patients with high and low levels of protein expression
or metastasis. P-value was obtained using the log-rank test of the difference. (A) X-linked-chromosome inhibitor of apoptosis (XIAP) protein;
(B) Nuclear factor- κB (NF-κB).
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Kaplan-Meier analysis was used to calculate the impact
of classic clinicopathologic features and protein expres-
sion on survival (Table 3, Figure 2). Differentiation and
high expression of XIAP and NF-κB were associated
with decreased survival (P < 0.05), whereas other clinico-
pathological variables were not significant. Cox regression
analysis revealed a statistically significant correlation
among differentiation and XIAP expression (P < 0.05,
Table 4).
Discussion
Compared with the surgery alone, earlier studies have
suggested that postoperative prophylactic radiotherapy
produces a better prognosis in esophageal cancer pa-
tients [24-26]. However, not all patients benefit from
radiotherapy; some even have a shorter survival time. A
good tumor response is usually responsible for an excel-
lent prognosis. Thus, biomarkers that can predict radi-
ation response and outcomes before treatment are needed
and a high level of apoptotic tumor cells is a predictive
marker for tumor response in antitumor therapy. Among
the numerous proteins involved in apoptosis regulation,
IAP proteins play an important role. The human IAP
family is composed of eight proteins: NAIP (BIRC1),
c-IAP1 (BIRC2), c-IAP2 (BIRC3), XIAP (BIRC4), survi-
vin (BIRC5), Apollon/Bruce (BIRC6), ML-IAP (BIRC7 or
livin) and ILP-2 (BIRC8). Furthermore, XIAP is the only
member of this family able to directly inhibit both the
initiation and execution phase of the caspase cascadeTable 4 Multivariate Cox proportional hazards analysis
for overall survival
Variables Overall survival P
RR 95% CI
XIAP 4.68 1.60 to 13.67 0.005
Differentiation 3.55 1.51 to 8.37 0.004which is crucial to mediate the controlled demise of
malignant cells. More widely, XIAP has been found to
be frequently overexpressed in most human cancer
cells and renders cells resistant to cancer treatment
and so XIAP has received interest as a therapeutic tar-
get [9,27]. Recently, increasingly more research studies
have found that small-molecule XIAP inhibitors could
enhance irradiation-induced apoptosis in most cancer
cells [28-30]. However, the prognosis of XIAP for post-
operative prophylactic radiotherapy in ESCC patients
has not been extensively investigated. On the other
hand, the most important contribution of IAPs to cell
survival and tumorigenesis resides in the ability of XIAP
to regulate ubiquitin-dependent activation of NF-κB [31].
The high constitutive nuclear activation of NF-κB activa-
tion has been detected in many solid cancers, which attri-
bute mainly to the development and progression of cancer
such as proliferation, migration and apoptosis [21]. A
positive correlation was observed between NF-κB and
nodal metastasis in ESCC, but the clinical significance for
NF-κB in predicting associated outcomes and its correl-
ation with XIAP in patients receiving postoperative radio-
therapy for ESCC have not been reported before.
In this study, we found that XIAP and NF-κB were
highly expressed in ESCC specimens. Immunostaining
showed the expression of XIAP in the resected ESCC
specimens to be mostly in the cytoplasm, whereas NF-
κB expression was predominantly localized in the nu-
cleus (Figure 1). Consistently, our results showed that
the high level of XIAP expression correlated significantly
with both tumor differentiation and p-TNM stage, and
the same results were obtained for NF-κB. Next, the
statistical analysis shows that the in vivo correlation
between XIAP and NF-κB expression is a highly sig-
nificant association. This means NF-κB may be one of
XIAP-related interacting partners. However, the exact
molecular basis by which XIAP might interact with
NF-κB remains to be clarified in vivo. Overall, the
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well also be related to the genetic changes implicated
in ESCC radiosensitivity.
Previous investigation has largely focused on the prog-
nostic value of NF-κB in solid cancer, but there have
been few reports about that of XIAP [19,32,33]. More-
over, the prognostic value of XIAP for radiotherapy in
ESCC is not clear. Based on our observation of 78 pa-
tients with ESCC, our study explores the hypothesis that
overexpression of XIAP and NF-κB is predictive of shorter
survival in ESCC patients following surgery and postoper-
ative. It is generally considered that patients will benefit
greatly from antitumor therapy if available accurate infor-
mation about the likely outcomes before treatment is
started can be obtained. Consequently, further study is
needed to elucidate markers or combinations of markers
which best reflect the effects of radiotherapy in ESCC.
Such markers might prove valuable not only as clinical
predictors, but also as targets for ESCC treatment: for ex-
ample, treatment might result in increased sensitivity if
these abnormalities of function and expression return to
normal.
Conclusion
In conclusion, high level of XIAP expression was an in-
dependent unfavorable prognostic indicator in ESCC pa-
tients treated with radiotherapy after surgery. This might
be useful in helping clinicians to choose, with more ac-
curacy, the best clinical policy and therapy in patients.
Furthermore, we will be able to focus in future on both
the prognostic and treatment value of XIAP.
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